**Background**
The phosphatidylinositol 3-kinase (PI3K) pathway is one of the most frequently dysregulated signaling pathways in human malignancies, playing a critical role in cell growth, proliferation, and survival. Overactivation of this pathway, often due to mutations in PI3K or loss of the tumor suppressor PTEN, contributes significantly to tumor progression and resistance to therapy. The mammalian target of rapamycin (mTOR) serves as a key downstream effector of PI3K, and its inhibition is a primary goal in oncology research. Because the PI3K/mTOR axis is central to many oncogenic processes, developing potent inhibitors that can target multiple nodes of this pathway is essential for overcoming compensatory feedback mechanisms. In this context, we will introduce a dual PI3K and mTOR inhibitor – Dactolisib.
**Definition**
Dactolisib (also known as BEZ235) is an imidazo[4,5-c]quinoline derivative that acts as a potent dual inhibitor of PI3K and mTOR. According to the Dactolisib description, it exhibits high potency against PI3K isoforms with IC50 values of 4, 75, 7, and 5 nM for PI3Kα, β, γ, and δ, respectively, while also inhibiting both mTORC1 and mTORC2.
**In Vitro and In Vivo Studies**
The Dactolisib biological activity is characterized by its ability to bind to the ATP-binding cleft of its target enzymes. Dactolisib in vitro studies demonstrate that the compound is equally active against mutant forms of PI3Kα, specifically the E545K (IC50 = 5.7 nM) and H1047R (IC50 = 4.6 nM) mutations. In human tumor cell lines, Dactolisib effectively blocks dysfunctional PI3K pathway activation, leading to G1 cell cycle arrest. Notably, in PTEN-null cell lines such as PC3M and U87MG, the compound induces a dose-dependent reduction in cell proliferation with an average GI50 ranging from 10 to 12 nM. Furthermore, the compound is known to influence Dactolisib Autophagy and other cellular survival mechanisms.
Dactolisib In Vivo evaluations show that the compound is well tolerated and can induce disease stasis when administered orally. At an oral dose of 50 mg/kg, Dactolisib rapidly appears in the plasma, reaching a Cmax of 1.68 μM at 0.5 h and maintaining a C24h of 0.03 μM. Additionally, it has been observed to enhance the efficacy of other anticancer agents in combination therapies. In conclusion, Dactolisib is a potent, orally available dual PI3K/mTOR inhibitor that holds significant promise for Dactolisib Cancer research.
Keywords
Dactolisib, 1028385-32-1, BEZ235, NVP-BEZ 235, BEZ 235, BEZ-235, PI3K, mTOR, Autophagy, Phosphoinositide 3-kinase, Mammalian target of Rapamycin, Inhibitor, inhibitor, inhibit
References